NCT05441826View on ClinicalTrials.gov

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

May 3, 2023

Study Completion Date

October 12, 2023

Conditions
Minimal Change DiseaseFocal Segmental Glomerulosclerosis
Interventions
DRUG

VB119

Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.

Trial Locations (1)

12208

Clinical Research Site, Albany

Sponsors

Lead Sponsor

Tenet Medicines
All Listed Sponsors
lead

Tenet Medicines

INDUSTRY